| |
|
Interactive Case Discussion
Case presentation: Greyzone Lymphoma
Case presentation: Anti-PD1 Failure
Case presentation: COVID19 immunity in lymphoma
Case presentation: Primary progressive HL
|
|
|
Advanced Stages
Improving BEACOPP
Improving ABVD
WS Report: Time for Innovative Trial Designs
|
|
|
|
|
|
Seminars
and
Workshops
(parallel sessions)
Seminar:
Living beyond Lymphoma
Seminar:
The HL Microenvironment
Workshop:
PET beyond Deauville
Workshop:
Older Patients
|
|
|
|
|
|
|
|
|
|
|
|
Emerging Cellular Therapies – a Role in HL?
Emerging indications for cellular therapy
Cellular Therapy in HL
New concepts in cellular therapy
|
|
|
Special Situations in HL
HL in Pregnancy
HIV-positive HL
alloSCT in the era of anti-PD1
|
|
|
|
|
|
|
|
|
|
|
|
|
Seminars
and
Workshops
(parallel sessions)
Seminar:
Radiotherapy
Workshop:
Bringing Liquid Biopsy to Patients
Seminar:
Learning from Pediatric HL
Workshop:
NLPHL
Workshop:
Time for innovative trial design
|
|
|
Living beyond Lymphoma
Heart & Lung Toxicity a er HL Treatment
Informed decision making
WS Report: Living beyond Lymphoma
|
|
|
Genomics, Biology and Microenvironment
Biological Classi cation of HL by Liquid Biopsy
Single Cell Transcriptomics of HL
WS Report: Bringing Liquid Biopsy to Patients
|
|
|
|
|
|
|
|
|
|
|
|
|
Satellite Symposium
|
|
|
Satellite Symposium
|
|
|
Satellite Symposium
|
|
|
|
|
|
|
|
|
|
|
|
|
Early Stages
Standard treatment of early-stage HL (Note: with RAPID Update)
Individual risk assessment of RT in HL
WS Report: NLPHL
|
|
|
Older and Frail Patients
Treatment Allocation in Older HL Patients
Managing an Older Lymphoma Patient
WS Report: Older Patients
|
|
|
Relapsed / Refractory HL
1ˢᵗ Relapse of HL
Novel developments in R/R HL
|
|
|
|
|
|
|
|
|
Closing Remarks
Conference Highlights
|
|
|
|
|
|
Satellite Symposium
|
|
|
Satellite Symposium
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Opening and Award Ceremony
|
|
|
Immunotherapy
Immunotherapy approaches in 1ˢᵗ-line HL
How I currently treat HL with immunotherapy
Vision Corner
|
|
|
|
|
|
Poster Session and Welcome Reception
|
|
|
|
|
| |
|
|
|
| |
|
|
|